Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.58 |
| ▸ | CTSB | P07858 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | CTDSP1 | Q9GZU7 | 3/20 | 0.52 |
| ▸ | CASP6 | P55212 | 2/20 | 0.52 |
| ▸ | NSD2 | O96028 | 2/20 | 0.52 |
| ▸ | RECQL | P46063 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | APEX1 | P27695 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | MYC | P01106 | 2/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.48 |
| ▸ | PLK1 | P53350 | 1/20 | 0.46 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL438258 | 0.80 | ALDH1A1 (0.62) | TDP1ALDH1A1L3MBTL1POLBPKM | |
| SCHEMBL437676 | 0.77 | ALDH1A1 (0.67) | TDP1ALDH1A1L3MBTL1POLBCTDSP1 | |
| SCHEMBL436568 | 0.77 | ALDH1A1 (0.53) | TDP1ALDH1A1L3MBTL1POLBCTDSP1 | |
| SCHEMBL5922325 | 0.76 | NOTUM (0.67) | ALDH1A1NOTUMPLK1CHRNA7 | |
| SCHEMBL10205950 | 0.75 | PLK1 (0.54) | ALDH1A1L3MBTL1POLBPLK1HPGD | |
| SCHEMBL27542192 | 0.75 | NOTUM (0.70) | ALDH1A1PKMNOTUMPLK1KDM4E | |
| SCHEMBL14280209 | 0.74 | HTT (0.55) | ALDH1A1L3MBTL1PKMPLK1KDM4E | |
| SCHEMBL13430836 | 0.74 | TDP1 (1.00) | TDP1CTSBALDH1A1L3MBTL1POLB | |
| SCHEMBL2449412 | 0.73 | PLK1 (0.73) | ALDH1A1PKMMYCNOTUMPLK1 | |
| SCHEMBL436563 | 0.71 | PLA2G10 (0.43) | ALDH1A1POLBKDM4EHSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217073-B2 | Pyrrole derivatives as therapeutic compounds | MYREXIS, INC. (US) | 2012-07-10 | — | — | US | claimed |
| US-20120065241-A1 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | MYREXIS, INC. (US) | 2012-03-15 | — | — | US | claimed |
| EP-1928827-B1 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS INC (US) | 2012-08-22 | — | — | EP | disclosed |
| US-8217073-B2 | Pyrrole derivatives as therapeutic compounds | MYREXIS, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-8217073-B2 | Pyrrole derivatives as therapeutic compounds | MYREXIS, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-8217073-B2 | Pyrrole derivatives as therapeutic compounds | MYREXIS, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-20120065241-A1 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | MYREXIS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065241-A1 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | MYREXIS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065241-A1 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | MYREXIS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20100216862-A1 | Pyrrole Derivatives As Therapeutic Compounds | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216862-A1 | Pyrrole Derivatives As Therapeutic Compounds | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-08-26 | — | — | US | disclosed |
| US-7714022-B2 | Pyrrole derivatives as therapeutic compounds | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20090253768-A1 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INCORPORATED (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090253768-A1 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INCORPORATED (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090253768-A1 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INCORPORATED (US) | 2009-10-08 | — | — | US | disclosed |
| US-20080249158-A1 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS, INCORPORATED (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249158-A1 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS, INCORPORATED (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249158-A1 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS, INCORPORATED (US) | 2008-10-09 | — | — | US | disclosed |
| WO-2008031034-A2 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| WO-2007038684-A2 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS, INC. (US) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065241-A1 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | NLN, SLC18A2, GOLT1B | TDP1 375/4885CTSB 734/4885ALDH1A1 2759/4885 |
| US-20100216862-A1 | Pyrrole Derivatives As Therapeutic Compounds | APP, PSEN2, PSEN1 | TDP1 224/4885CTSB 1119/4885ALDH1A1 4389/4885 |
| US-20080249158-A1 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | APP, PSEN2, PSEN1 | TDP1 224/4885CTSB 1119/4885ALDH1A1 4389/4885 |
| US-20090253768-A1 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | NLN, SLC18A2, GOLT1B | TDP1 375/4885CTSB 734/4885ALDH1A1 2759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.